on June 30, 2005
Published online before print June 30, 2005, doi: 10.1161/01.ATV.0000175767.46520.6a
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 22, 2005
Accepted on June 3, 2005
Atherosclerotic Lesion Development in a Novel Ovary-Intact Mouse Model of Perimenopause
Loretta P. Mayer *;
From the Department of Biological Sciences (L.P.M., C.A.D.), Northern Arizona University, Flagstaff; La Jolla Institute for Molecular Medicine (R.L.E., C.L.B.), San Diego, Calif; and the Department of Physiology (P.B.H.), University of Arizona, Tucson.
* To whom correspondence should be addressed. E-mail: Loretta.Mayer{at}nau.edu.
Objective--Since the unexpected results from the Women’s Health Initiative, the possible protective role of estrogen in preventing heart disease in perimenopausal and postmenopausal women is uncertain. This study examined atherosclerotic lesion development in ovariectomized versus follicle-depleted ovary-intact cholesterol-fed female low-density lipoprotein (LDL) receptor-deficient mice.
Methods and Results--We studied lesion development in LDL receptor-deficient mice that were ovariectomized or follicle depleted with 4-vinylcyclohexene diepoxide (VCD) to induce ovarian failure, then treated ± exogenous 17
-estradiol via pellet implant. At 120 days after start of cholesterol feeding, the extent of lesion in aorta and innominate artery was determined. Lesion area in both locations was similar in vehicle control, VCD-treated, and ovariectomized mice. Replacement with 17-estradiol caused lesion reduction (P<0.05) in both arterial locations, but it was most efficacious in suppressing innominate lesion area in VCD-treated mice (12.9±5.2%) compared with ovariectomized mice (40.0±6.04%).
Conclusions--Endocrine status associated with the follicle-depleted ovary influences exogenous estradiol effects during the development of atherosclerotic lesions and, in particular, inhibits lesion progression in the innominate artery.
Key words: atherosclerosis • estrogen supplementation • perimenopause model
Related Article:
- A Mouse Model of the Perimenopausal Transition: Importance for Cardiovascular Research
- J. Koudy Williams
Arterioscler Thromb Vasc Biol 2005 25: 1765-1766.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  J. I. Acosta, L. Mayer, J. S. Talboom, C. W. S. Tsang, C. J. Smith, C. K. Enders, and H. A. Bimonte-Nelson Transitional Versus Surgical Menopause in a Rodent Model: Etiology of Ovarian Hormone Loss Impacts Memory and the Acetylcholine System Endocrinology, September 1, 2009; 150(9): 4248 - 4259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Rivera, P. J. Christian, S. L. Marion, H. L. Brooks, and P. B. Hoyer Steroidogenic Capacity of Residual Ovarian Tissue in 4-Vinylcyclohexene Diepoxide-Treated Mice Biol Reprod, February 1, 2009; 80(2): 328 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Jackson, M. R. Bennett, E. A.L. Biessen, J. L. Johnson, and R. Krams Assessment of Unstable Atherosclerosis in Mice Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 714 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Banka, C. V. Lund, M. T.N. Nguyen, A. J. Pakchoian, B. M. Mueller, and B. P. Eliceiri Estrogen Induces Lung Metastasis through a Host Compartment-Specific Response. Cancer Res., April 1, 2006; 66(7): 3667 - 3672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh and B.-K. Yoon Controversies regarding hormone therapy: Insights from inflammation and hemostasis Cardiovasc Res, April 1, 2006; 70(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Williams A Mouse Model of the Perimenopausal Transition: Importance for Cardiovascular Research Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1765 - 1766. [Full Text] [PDF]
|
|